Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir.

Autor: Xiomara V Thomas, Joep de Bruijne, James C Sullivan, Tara L Kieffer, Cynthia K Y Ho, Sjoerd P Rebers, Michel de Vries, Hendrik W Reesink, Christine J Weegink, Richard Molenkamp, Janke Schinkel

Publikováno v: PLoS ONE, Vol 7, Iss 7, p e41191 (2012)

BACKGROUND & AIMS: Telaprevir, a hepatitis C virus NS3/4A protease inhibitor has significantly improved sustained viral response rates when given in combination with pegylated interferon alfa-2a and ribavirin, compared with current standard of care i

Externí odkaz: https://doaj.org/article/2e4b8e9596954b95a4c8867de164ece3

Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up

Autor: Xun Qi, Adrian Streinu-Cercel, Heng Chi, Fehmi Tabak, Qing Xie, Mircea Diculescu, Margo J. H. van Campenhout, Elke Verhey, Harry L.A. Janssen, Willem P. Brouwer, Bettina E. Hansen, Hendrik W. Reesink, Włodzimierz Mazur, Rob J. de Knegt, Krzysztof Simon, Ningping Zhang, Meral Akdogan, J. Wang, S. Guo, Ramazan Idilman

Publikováno v: Journal of viral hepatitis, 26(1), 109-117. Wiley-Blackwell
Journal of Viral Hepatitis, 26(1), 109-117. Wiley-Blackwell Publishing Ltd

Addition of peginterferon alpha (PEG-IFN add-on) to entecavir (ETV) treatment after a short lead-in phase results in more response than ETV monotherapy in HBeAg-positive chronic hepatitis B infection (CHB). This study is the first to assess long-term

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2add2b6196a6377758f5b7c0a3a713e1
https://doi.org/10.1111/jvh.12997

Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load

Autor: M. Koot, F. Stelma, Sebastiaan Weijer, Annikki de Niet, R. Bart Takkenberg, Hans L. Zaaijer, Sjoerd D. Kuiken, Louis Jansen, S.B. Willemse, Joanne Verheij, Hendrik W. Reesink, Ulrich Beuers, Richard Molenkamp, Carin M.J. van Nieuwkerk

Publikováno v: de Niet, A, Jansen, L, Stelma, F, Willemse, S B, Kuiken, S D, Weijer, S, van Nieuwkerk, C M J, Zaaijer, H L, Molenkamp, R, Takkenberg, R B, Koot, M, Verheij, J, Beuers, U & Reesink, H W 2017, ' Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load : a randomised controlled, open-label trial ', The Lancet Gastroenterology and Hepatology, vol. 2, no. 8, pp. 576-584 . https://doi.org/10.1016/S2468-1253(17)30083-3
lancet. Gastroenterology & hepatology, 2(8), 576-584. Elsevier Limited
The Lancet Gastroenterology and Hepatology, 2(8), 576-584. Elsevier Ltd

BACKGROUND: Antiviral treatment is currently not recommended for patients with chronic hepatitis B with a low viral load. However, they might benefit from acquiring a functional cure (hepatitis B surface antigen [HBsAg] loss with or without formation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1e098df049e127f4a43b75385adab4b
https://doi.org/10.1016/s2468-1253(17)30083-3

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C

Autor: Michael Huang, Adam Pavlicek, Ad C. van Nuenen, S.B. Willemse, Neeltje A. Kootstra, J. Marleen L. de Vree, F. Stelma, Janke Schinkel, Svend Rietdijk, Salah Hadi, P. Grint, Eva van der Veer, Meike H. van der Ree, S. Neben, Kai Liu, Richard Molenkamp, Jacqueline Blem, Marc van der Valk, Amy K Patick, John Grundy, Neil W. Gibson, Marten Harbers, Ulrich Beuers, Hendrik W. Reesink

Publikováno v: The Lancet, 389(10070), 709-717. ELSEVIER SCIENCE INC
Lancet, 389(10070), 709-717. Elsevier Limited

Summary Background miR-122 is an important host factor for hepatitis C virus (HCV) replication. The aim of this study was to assess the safety and tolerability, pharmacokinetics, and antiviral effect of a single dose of RG-101, a hepatocyte targeted

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2ada5969206c992947817864c14051a
https://doi.org/10.1016/S0140-6736(16)31715-9

Genome Wide Association Study Identifies Genetic Variants Associated with Early and Sustained Response to (Peg)Interferon in Chronic Hepatitis B Patients: The GIANT-B Study

Autor: Willem Pieter Brouwer, Henry L. Y. Chan, Pietro Lampertico, Jinlin Hou, Pisit Tangkijvanich, Hendrik W. Reesink, Wenhong Zhang, Alessandra Mangia, Tawesak Tanwandee, Giuseppe Montalto, Kris Simon, Necati Ormeci, Liang Chen, Fehmi Tabak, Fulya Gunsar, Robert Flisiak, Peter Ferenci, Meral Akdogan, Filiz Akyuz, Nattiya Hirankarn, Louis Jansen, Vincent Wai-Sun Wong, Roberta Soffredini, Xieer Liang, Shalom Chen, Zwier M. A. Groothuismink, Rosanna Santoro, Jerzy Jaroszewicz, Resat Ozaras, Karin Kozbial, Mayur Brahmania, Qing Xie, Watcharasak Chotiyaputta, Xun Qi, Monika Pazgan-Simon, Erkin Oztas, Elke Verhey, Noé R. Montanari, Jian Sun, Bettina E. Hansen, Andre Boonstra, Harry L. A. Janssen, GIANT-B Global Consortium

Publikováno v: SSRN Electronic Journal.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::27a93ec944f7f0632815601b01b9a4a0
https://doi.org/10.2139/ssrn.3224898